A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

703

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Non-Small-Cell Lung

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo

Sponsor

Bayer